Concepts (82)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 7 | 2020 | 69 | 2.960 |
Why?
|
| Atherosclerosis | 5 | 2020 | 100 | 2.070 |
Why?
|
| Interleukin-6 | 3 | 2020 | 51 | 0.890 |
Why?
|
| Polymorphism, Genetic | 2 | 2020 | 99 | 0.790 |
Why?
|
| Renal Dialysis | 3 | 2019 | 27 | 0.780 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 15 | 0.700 |
Why?
|
| Kidney Tubules | 1 | 2020 | 1 | 0.690 |
Why?
|
| Population Groups | 1 | 2020 | 9 | 0.680 |
Why?
|
| Apolipoprotein L1 | 1 | 2020 | 6 | 0.680 |
Why?
|
| Lipoproteins, LDL | 1 | 2020 | 9 | 0.670 |
Why?
|
| Kidney Diseases | 1 | 2020 | 38 | 0.670 |
Why?
|
| Tenofovir | 1 | 2020 | 171 | 0.630 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 198 | 0.630 |
Why?
|
| HIV Seropositivity | 1 | 2020 | 265 | 0.580 |
Why?
|
| Hospitalization | 1 | 2021 | 418 | 0.580 |
Why?
|
| C-Reactive Protein | 4 | 2020 | 96 | 0.560 |
Why?
|
| Adult | 8 | 2021 | 5913 | 0.530 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2016 | 4 | 0.520 |
Why?
|
| Vena Cava, Inferior | 1 | 2016 | 5 | 0.510 |
Why?
|
| Cardiac Volume | 1 | 2016 | 3 | 0.500 |
Why?
|
| Malnutrition | 1 | 2016 | 56 | 0.490 |
Why?
|
| Carotid Intima-Media Thickness | 4 | 2020 | 108 | 0.480 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2016 | 47 | 0.480 |
Why?
|
| Male | 7 | 2021 | 6754 | 0.460 |
Why?
|
| Middle Aged | 6 | 2021 | 3601 | 0.450 |
Why?
|
| Genotype | 3 | 2020 | 442 | 0.440 |
Why?
|
| Inflammation | 3 | 2020 | 104 | 0.400 |
Why?
|
| Female | 7 | 2021 | 9103 | 0.400 |
Why?
|
| Anti-HIV Agents | 1 | 2020 | 1324 | 0.370 |
Why?
|
| Humans | 9 | 2021 | 14537 | 0.360 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 1422 | 0.360 |
Why?
|
| Case-Control Studies | 3 | 2020 | 480 | 0.300 |
Why?
|
| Echocardiography | 3 | 2019 | 100 | 0.280 |
Why?
|
| Kidney Failure, Chronic | 2 | 2019 | 27 | 0.280 |
Why?
|
| Peritoneal Dialysis | 2 | 2016 | 10 | 0.250 |
Why?
|
| Cohort Studies | 2 | 2020 | 967 | 0.240 |
Why?
|
| Biomarkers | 2 | 2016 | 327 | 0.230 |
Why?
|
| Risk Factors | 2 | 2020 | 1475 | 0.220 |
Why?
|
| Survival Rate | 2 | 2021 | 96 | 0.200 |
Why?
|
| Length of Stay | 1 | 2021 | 43 | 0.180 |
Why?
|
| Pharmacogenomic Testing | 1 | 2020 | 1 | 0.170 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 62 | 0.170 |
Why?
|
| Nigeria | 1 | 2020 | 49 | 0.170 |
Why?
|
| HIV-2 | 1 | 2020 | 15 | 0.170 |
Why?
|
| Hospital Mortality | 1 | 2021 | 95 | 0.170 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2020 | 6 | 0.170 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 12 | 0.170 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 46 | 0.170 |
Why?
|
| Risk | 1 | 2020 | 87 | 0.170 |
Why?
|
| DNA | 1 | 2020 | 73 | 0.170 |
Why?
|
| Gene Frequency | 1 | 2020 | 122 | 0.160 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 370 | 0.160 |
Why?
|
| Prevalence | 2 | 2020 | 1192 | 0.160 |
Why?
|
| Research Design | 1 | 2020 | 124 | 0.160 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 411 | 0.150 |
Why?
|
| South Africa | 3 | 2020 | 7596 | 0.140 |
Why?
|
| Viral Load | 1 | 2020 | 819 | 0.130 |
Why?
|
| Spectrum Analysis | 1 | 2016 | 8 | 0.130 |
Why?
|
| Electric Impedance | 1 | 2016 | 8 | 0.130 |
Why?
|
| Heart | 1 | 2016 | 27 | 0.130 |
Why?
|
| Aged | 1 | 2021 | 1740 | 0.120 |
Why?
|
| Endotoxins | 1 | 2016 | 6 | 0.120 |
Why?
|
| Extracellular Fluid | 1 | 2016 | 5 | 0.120 |
Why?
|
| Edema | 1 | 2016 | 7 | 0.120 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 11 | 0.120 |
Why?
|
| Schistosomiasis | 1 | 2016 | 8 | 0.120 |
Why?
|
| Acute-Phase Proteins | 1 | 2016 | 14 | 0.120 |
Why?
|
| Anemia, Sickle Cell | 1 | 2016 | 13 | 0.120 |
Why?
|
| Carrier Proteins | 1 | 2016 | 23 | 0.120 |
Why?
|
| Nutritional Status | 1 | 2016 | 76 | 0.120 |
Why?
|
| Body Composition | 1 | 2016 | 153 | 0.110 |
Why?
|
| Malaria | 1 | 2016 | 213 | 0.100 |
Why?
|
| HIV-1 | 1 | 2020 | 1260 | 0.100 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2019 | 2 | 0.040 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2019 | 65 | 0.040 |
Why?
|
| Glomerulonephritis | 1 | 2016 | 7 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 30 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 370 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2016 | 353 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2016 | 167 | 0.030 |
Why?
|
| Developing Countries | 1 | 2016 | 400 | 0.030 |
Why?
|
| Hypertension | 1 | 2016 | 419 | 0.020 |
Why?
|